Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Carparts.Com Inc (PRTS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Carparts.Com IncTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Carparts.Com Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Carparts.Com Inc trades at $10 (market cap $72.26M), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: Carparts.Com Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.

PRTSXBI
Market Cap
$72.26M
Sector
Consumer CyclicalBroad Market / Factor
52-Week High
$10.00$169.55
52-Week Low
$3.88$93.43
Enterprise Value
$85.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Carparts.Com Inc

CarParts.com (PRTS) trades at $9.50, up 2.15% with strong technical momentum and bullish moving average signals. The company shows improving quarterly earnings performance with three consecutive beats, though it remains unprofitable with negative margins. Recent developments include a new $25 million credit facility and Nasdaq compliance restoration, while analyst sentiment leans positive with 60% buy ratings.

The outlook suggests cautious optimism given improving earnings trajectory and technical strength, but significant risks persist from sustained losses, negative cash flow, and competitive pressures. Investment appeal hinges on the company's ability to translate revenue stabilization into profitability while managing operational challenges in the automotive e-commerce sector.

State Street SPDR S&P Biotech ETF

XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.

Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Carparts.Com Inc

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

Read more on PRTS

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI